本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Viking Therapeutics, Inc.

32.01
-0.0600-0.19%
盤後32.200.1900+0.59%19:59 EDT
成交量:339.45萬
成交額:1.09億
市值:35.95億
市盈率:-27.76
高:33.16
開:32.16
低:31.28
收:32.07
資料載入中...
2024/10/23

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/23

重要事件披露

Form 8-K - Current report
2024/10/18

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/14

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/07/30

關聯方擬減持公告

Form144 | Viking Therapeutics高管Greg Zante擬減持16136股,總價約92.2萬美元
2024/07/30

關聯方擬減持公告

Form144 | Viking Therapeutics高管Brian Lian擬減持115,859股,總價約667萬美元
2024/07/30

關聯方擬減持公告

Form144 | Viking Therapeutics高管Marianna Mancini擬減持18026股,總價約102.99萬美元
2024/07/25

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/25

重要事件披露

Form 8-K - Current report
2024/06/04

重要事件披露

Form 8-K - Current report
2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments